Details of the Drug Combinations

General Information of This Drug (ID: DMNE7L3)

Drug Name

CC-220 DMNE7L3

Synonyms

AC1OEW2H; NPD6561; MCULE-9299015048; BCP9000573; BCP0726000266

Indication

Disease Entry	ICD 11	Status	REF
Sarcoidosis	4B20.5	Phase 2	[1]
Systemic lupus erythematosus	4A40.0	Phase 2	[2]
Multiple myeloma	2A83	Phase 1	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dexamethasone + CC-220	DCEK6HT	Dexamethasone	Multiple Myeloma	[4]
Dexamethasone + CC-220	DCMDEES	Dexamethasone	Multiple Myeloma	[4]
Itraconazole + CC-220	DCV7DHT	Itraconazole	Pharmacokinetics	[5]
Rifampicin + CC-220	DCMCXV3	Rifampicin	Pharmacokinetics	[5]
Dexamethasone + CC-220	DCPZJ2T	Dexamethasone	Multiple Myeloma	[6]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02185040) A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT02773030) A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
5	ClinicalTrials.gov (NCT02820935) Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects
6	ClinicalTrials.gov (NCT06216158) Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma